Literature DB >> 8929762

Influences on cognitive heterogeneity in schizophrenia.

G Goldstein1, W J Shemansky.   

Abstract

A study was conducted of diagnostic reliability, clinical, demographic, iatrogenic, and neurological comorbidity influences on heterogeneity in cognitive function among schizophrenic patients. Comparisons were made between a previously described (Goldstein, 1990) retrospective sample of clinically diagnosed schizophrenic patients and a new sample based on a prospective study of patients meeting strict DSM-III-R diagnostic criteria for schizophrenia. A cluster analysis of a brief battery of cognitive tests suggested a four cluster solution in both samples. The cluster pattern was found to be similar in both samples, indicating that diagnostic unreliability is unlikely to be strongly associated with heterogeneity. Age, general intelligence, and education were found to have significant influences on cluster membership, with length of illness and hospitalization having less robust influences. It was concluded that heterogeneity has a relatively mild relationship with the various influences studied, but a great deal of the diversity in level and pattern of cognitive function found among schizophrenic patients is likely to be a function of heterogeneity within the disorder itself.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8929762     DOI: 10.1016/0920-9964(95)00040-2

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  14 in total

Review 1.  Sources of heterogeneity in schizophrenia: the role of neuropsychological functioning.

Authors:  B E Seaton; G Goldstein; D N Allen
Journal:  Neuropsychol Rev       Date:  2001-03       Impact factor: 7.444

2.  Level and pattern of neuropsychological functioning in early-onset psychoses.

Authors:  D-M Walker; P J Standen
Journal:  Eur Child Adolesc Psychiatry       Date:  2011-10-12       Impact factor: 4.785

3.  Cognitive variability in psychotic disorders: a cross-diagnostic cluster analysis.

Authors:  K E Lewandowski; S H Sperry; B M Cohen; D Ongür
Journal:  Psychol Med       Date:  2014-04-07       Impact factor: 7.723

Review 4.  First- and second-generation antipsychotic medication and cognitive processing in schizophrenia.

Authors:  Thomas W Weickert; Terry E Goldberg
Journal:  Curr Psychiatry Rep       Date:  2005-08       Impact factor: 5.285

5.  Functional connectivity in distinct cognitive subtypes in psychosis.

Authors:  Kathryn E Lewandowski; Julie M McCarthy; Dost Öngür; Lesley A Norris; Geoffrey Z Liu; Richard J Juelich; Justin T Baker
Journal:  Schizophr Res       Date:  2018-08-17       Impact factor: 4.939

6.  Neuropsychological impairment in first-episode and chronic schizophrenic patients.

Authors:  M Albus; W Hubmann; C Ehrenberg; U Forcht; F Mohr; N Sobizack; C Wahlheim; S Hecht
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1996       Impact factor: 5.270

7.  Neurocognitive profiles in the prodrome to psychosis in NAPLS-1.

Authors:  Eva Velthorst; Eric C Meyer; Anthony J Giuliano; Jean Addington; Kristin S Cadenhead; Tyrone D Cannon; Barbara A Cornblatt; Thomas H McGlashan; Diana O Perkins; Ming T Tsuang; Elaine F Walker; Scott W Woods; Carrie E Bearden; Larry J Seidman
Journal:  Schizophr Res       Date:  2018-08-02       Impact factor: 4.939

Review 8.  A neurocognitive animal model dissociating between acute illness and remission periods of schizophrenia.

Authors:  Martin Sarter; Vicente Martinez; Rouba Kozak
Journal:  Psychopharmacology (Berl)       Date:  2008-07-10       Impact factor: 4.530

Review 9.  Cognitive heterogeneity in schizophrenia.

Authors:  Eileen M Joyce; Jonathan P Roiser
Journal:  Curr Opin Psychiatry       Date:  2007-05       Impact factor: 4.741

10.  Brain structure and function correlates of cognitive subtypes in schizophrenia.

Authors:  Daniel Geisler; Esther Walton; Melissa Naylor; Veit Roessner; Kelvin O Lim; S Charles Schulz; Randy L Gollub; Vince D Calhoun; Scott R Sponheim; Stefan Ehrlich
Journal:  Psychiatry Res       Date:  2015-08-21       Impact factor: 3.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.